Deliberately provoking local inflammation drives tumors to become their own protective vaccine site

International Immunology

Volumn 20, Issue 11, 2008, Pages 1467-1479

  Jackaman, Connie ^a   Lew, Andrew M ^b   Zhan, Yifan ^b   Allan, Jane E ^a   Koloska, Biljana ^c   Graham, Peter T ^c   Robinson, Bruce W S ^a   Nelson, Delia J ^a,c  

^a CURTIN UNIVERSITY   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Agonist anti CD40 antibody; Anti tumor immunity; IL 2; Neutrophils; T cells

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 ANTIBODY; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER REGRESSION; CANCER SIZE; CD8+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG TARGETING; FEMALE; IMMUNOGENICITY; INFLAMMATION; MONOTHERAPY; MOUSE; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; ASBESTOS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; INJECTIONS, INTRAVENOUS; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; MESOTHELIOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECOMBINANT PROTEINS;

EID: 54949110593     PISSN: 09538178     EISSN: 14602377     Source Type: Journal    
DOI: 10.1093/intimm/dxn104     Document Type: Article

References (35)

1. Caminschi, I., Venetsanakos, E., Leong, C. C., Garlepp, M. J., Scott, B. and Robinson, B. W. 1998. Interleukin-12 induces an effective antitumor response in malignant mesothelioma. Am. J. Respir. Cell Mol. Biol. 19:738.
2. Christmas, T. I., Manning, L. S., Garlepp, M. J., Musk, A. W. and Robinson, B. W. 1993. Effect of interferon-alpha 2a on malignant mesothelioma. J. Interferon Res. 13:9.
3. Bielefeldt-Ohmann, H., Fitzpatrick, D. R., Marzo, A. L., Jarnicki, A. G., Musk, A. W. and Robinson, B. W. 1995. Potential for interferon-alpha-based therapy in mesothelioma: Assessment in a murine model. J Interferon Cytokine Res. 15:213.
4. Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. and Fitzpatrick, D. R. 1995. Interleukin-6 involvement in mesothelioma pathobiology: Inhibition by interferon alpha immunotherapy. Cancer Immunol. Immunother.0 40:241.
5. Upham, J. W., Musk, A. W., van Hazel, G., Byrne, M. and Robinson, B. W. 1993. Interferon alpha and doxorubicin in malignant mesothelioma: A phase II study. Aust. N. Z. J. Med. 23:683.
6. Stumbles, P. A., Himbeck, R., Frelinger, J. A., Collins, E. J., Lake, R. A. and Robinson, B. W. 2004. Cutting edge: Tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic anti-CD40 activation. J. Immunol. 173:5923.
7. Yu, P., Rowley, D. A., Fu, Y. X. and Schreiber, H. 2006. The role of stroma in immune recognition and destruction of well-established solid tumors. Curr. Opin. Immunol. 18:226.
8. Ganss, R., Arnold, B. and Hammerling, G. J. 2004. Mini-review: overcoming tumor-intrinsic resistance to immune effector function. Eur. J. Immunol. 34:2635.
9. Amador, J. F., Vazquez, A. M., Cabrera, L., Barral, A. M., Gendelman, R. and Jondal, M. 1991. Toxic effects of interleukin-2-activated lymphocytes on vascular endothelial cells. Nat. Immun. Cell Growth Regul. 10:207.
10. -tumors through induction of strong systemic cytotoxic T lymphocyte immunity. Proc. Natl Acad. Sci. USA 99:5561.
11. Vonderheide, R. H., Flaherty, K. T., Khalil, M. et al. 2007. Clinical activity and immune modulation in cancer patients treated with CP-870893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25:876.
12. Broomfield, S., Currie, A., van der Most, R. G. et al. 2005. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 65:7580.
13. Nowak, A. K., Robinson, B. W. and Lake, R. A. 2003. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 63:4490.
14. + cell responses. J. Immunol. 170:2727.
15. + T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med. 13:354.
16. Blankenstein, T., Rowley, D. A. and Schreiber, H. 1991. Cytokines and cancer: Experimental systems. Curr. Opin. Immunol. 3:694.
17. Yu, P., Lee, Y., Wang, Y. et al. 2007. Targeting the primary tumor to generate CTL for the effective eradication of spontaneous metastases. J. Immunol. 179:1960.
18. Davidson, J. A., Musk, A. W., Wood, B. R. et al. 1998. Intralesional cytokine therapy in cancer: A pilot study of GM-CSF infusion in mesothelioma. J. Immunother. 21:389.
19. Robinson, B. W., Mukherjee, S. A., Davidson, A. et al. 1997. 1998. Cytokine gene therapy or infusion as treatment for solid human cancer. J. Immunother. 1997. 21:211.
20. + T cells that mediate destruction of tumor cells and tumor-associated vasculature: A novel mechanism for IL-2. J. Immunol. 171:5051.
21. Mukherjee, S., Haenel, T., Himbeck, R. et al. 2000. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: Persistent transgene expression despite antibody generation. Cancer Gene Ther. 7:663.
22. Welniak, L. A., Shorts, L., Subleski, J., Blazar, B. R., Wiltrout, R. H. and Murphy, W. J. 2004. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organspecific effects. Biol. Blood Marrow Transplant. 10:534.
23. Zhan, Y., Corbett, A. J., Brady, J. L., Sutherland, R. M. and Lew, A. M. 2000. Delayed rejection of fetal pig pancreas in CD4 cell deficient mice was correlated with residual helper activity. Xenotransplantation 7:267.
24. Davis, M. R., Manning, L. S., Whitaker, D., Garlepp, M. J. and Robinson, B. W. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer 52:881.
25. Fleming, T. J., Fleming, M. L. and Malek, T. R. 1993. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte-differentiation antigen (Gr-1) detects members of the Ly-6 family. J. Immunol. 151:2399.
26. Nelson, D. J., Mukherjee, S., Bundell, C., Fisher, S., van Hagen, D. and Robinson, B. 2001. Tumor progression despite efficient tumor antigen cross-presentation and effective "arming" of tumor antigen-specific CTL. J. Immunol. 166:5557.
27. Nelson, D. J., Robinson, B. W., Allan, J. and van der Most, R. 2005. Gene therapy of mesothelioma. Expert Opin. Biol. Ther. 5:1039.
28. Hamzah, J., Nelson, D., Moldenhauer, G., Arnold, B., Hammerling, G. J. and Ganss, R. 2008. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J. Clin. Invest. 118:1691.
29. Schoenberger, S. P., Toes, R. E., van der Voort, E. I., Offringa, R. and Melief, C. J. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
30. Lichtenstein, A. and Kahle, J. 1985. Anti-tumor effect of inflammatory neutrophils: Characteristics of in vivo generation and in vitro tumor cell lysis. Int. J. Cancer 35:121.
31. Otten, M. A., Rudolph, E., Dechant, M. et al. 2005. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors. J. Immunol. 174:5472.
32. + T cell responses in the heart. Am. J Pathol. 163:2413.
33. +) effector T-cell generation in rats by selective depletion of neutrophils in vivo using a monoclonal antibody. Int. J. Cancer 54:131.
34. + T cells in the liver in a pregnant mouse model of Chlamydophila abortus (Chlamydia psittaci serotype 1) infection. Infect. Immun. 68:1746.
35. + subsets from distinct myeloid lineages have opposite effects on T cell expansion. J. Leukoc. Biol. 81:1205.